Report Highlights

U.S. Lung Function Testing: Market Overview

The U.S. lung function tests market is one of the most mature pulmonary diagnostics segments globally, anchored by a diagnostic pathway that begins with spirometry under CPT code 94010 and escalates to body plethysmography, diffusion capacity (DLCO) testing, and bronchoprovocation challenges. Its 2024 value of USD 0.78 billion reflects high testing rates among Medicare beneficiaries with COPD and asthma, which keeps per-capita utilization well above many peer markets in Europe and Asia.

Structurally, the U.S. market differs from global norms in its reliance on hospital outpatient departments and independent pulmonary function laboratories that bill Medicare fee schedules, rather than the point-of-care devices common in Europe. Equipment replacement cycles run seven to ten years, so growth comes mainly from upgrades to digital, software-integrated systems and from new ambulatory sites rather than first-time hospital purchases.

Growth Drivers in U.S. Lung Function Testing

Demand is driven first by chronic respiratory disease prevalence. The CDC reports more than 16 million American adults diagnosed with COPD and roughly 25 million people with asthma, both conditions requiring serial spirometry to confirm diagnosis, grade severity, and track therapy response. Second, the population aged 65 and older, which the Census Bureau places near 58 million, generates sustained diagnostic volume because obstructive disease incidence rises sharply after age 60.

Third, post-COVID-19 pulmonary follow-up has created durable demand for DLCO and spirometry testing, since many survivors required structured lung function assessment for persistent symptoms. National Heart, Lung, and Blood Institute funding for chronic lung disease research and Medicare coverage of codes 94726 and 94729 further sustain adoption across academic and community pulmonary practices nationwide.

Market Restraints and Entry Barriers

The FDA regulates diagnostic spirometers as Class II devices under 21 CFR 868.1840, requiring 510(k) premarket clearance with predicate-device comparisons and performance data against ATS/ERS technical standards. Laboratories also need CLIA certification under 42 CFR Part 493 for testing, and hospital buyers frequently demand multi-year service contracts that lock in incumbent vendors such as Vyaire Medical, COSMED, and Schiller once equipment is installed across a network.

Staffing presents a second barrier, because many accredited pulmonary function labs require Registered Pulmonary Function Technologist credentials, and the shortage of qualified technologists limits lab expansion regardless of equipment availability. Group purchasing agreements through Vizient and Premier add price pressure, while Medicare fee schedule constraints on codes such as 94010 compress reimbursement margins for independent labs investing in capital equipment.

Market Opportunities in the U.S.

The most immediate opportunity sits in remote and home spirometry tied to chronic disease management. Remote physiologic monitoring codes 99453 through 99458 allow providers to bill for at-home device setup and data review, and an analyst estimate places the addressable home spirometry segment near USD 85 million by 2028, driven by COPD patients who require frequent functional reassessment between clinic visits.

A second opportunity lies in drug-linked monitoring. Biologic therapies for severe asthma and antifibrotic treatments for idiopathic pulmonary fibrosis require periodic FVC and DLCO measurement, and with an estimated 100,000 U.S. patients with IPF, pharmaceutical sponsors increasingly fund lung function monitoring programs that route patients to certified labs, creating structured volume for vendors with clinical support capabilities.

Market at a Glance

Leading Market Participants

• Vyaire Medical
• COSMED
• MGC Diagnostics
• ndd Medical Technologies
• Vitalograph
• Nspire Health
• Mir
• Medisoft
• Schiller
• Koninklijke Philips

Regulatory and Policy Environment

The FDA's Center for Devices and Radiological Health oversees pulmonary function equipment through 21 CFR 868.1840 and the Quality Management System Regulation, which takes effect in February 2026 and aligns U.S. requirements with ISO 13485:2016. The FDA's 510(k) review goal is 90 days, but manufacturers should budget six to nine months for complete submissions, including bench testing against ATS/ERS spirometry standards and usability validation.

On the payment side, the Centers for Medicare and Medicaid Services publishes the Physician Fee Schedule each November, setting annual values for codes 94010, 94060, 94726, and 94729 with January 1 effective dates. The CDC's COPD surveillance program and NHLBI research grants shape diagnostic guidelines, but no direct equipment subsidy exists, so commercial viability depends on reimbursement stability and documented clinical outcomes.

Long-Term Outlook for U.S. Lung Function Testing

By 2032, the market is projected to reach USD 1.12 billion, with growth concentrated in ambulatory settings, remote monitoring, and drug-linked testing rather than hospital laboratory expansion. Portable spirometry and oscillometry systems will gain share in pulmonology clinics and primary care, while body plethysmographs and DLCO analyzers remain anchored in academic centers and large hospital systems.

Competitive dynamics will reward vendors that integrate devices with electronic health records, cloud data storage, and remote monitoring billing support. Incumbents with broad service networks retain advantages in hospital accounts, but smaller specialists that secure FDA clearance for home-use devices will capture the fastest-growing ambulatory and direct-to-patient channels through the forecast period.